These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 26723963)

  • 1. Reversible tongue muscle atrophy accelerated by early initiation of immunotherapy in anti-MuSK myasthenia gravis: A case report.
    Kitamura E; Takiyama Y; Nakamura M; Iizuka T; Nishiyama K
    J Neurol Sci; 2016 Jan; 360():10-2. PubMed ID: 26723963
    [No Abstract]   [Full Text] [Related]  

  • 2. MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis.
    Farrugia ME; Robson MD; Clover L; Anslow P; Newsom-Davis J; Kennett R; Hilton-Jones D; Matthews PM; Vincent A
    Brain; 2006 Jun; 129(Pt 6):1481-92. PubMed ID: 16672291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myopathy, muscle atrophy and tongue lipid composition in MuSK myasthenia gravis.
    Nikolić AV; Bačić GG; Daković MŽ; Lavrnić SĐ; Rakočević Stojanović VM; Basta IZ; Lavrnić DV
    Acta Neurol Belg; 2015 Sep; 115(3):361-5. PubMed ID: 25253293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibodies to AChR, MuSK and VGKC in a patient with myasthenia gravis and Morvan's syndrome.
    Díaz-Manera J; Rojas-García R; Gallardo E; Juárez C; Martínez-Domeño A; Martínez-Ramírez S; Dalmau J; Blesa R; Illa I
    Nat Clin Pract Neurol; 2007 Jul; 3(7):405-10. PubMed ID: 17611489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MRI evidence of early muscle atrophy in MuSK positive myasthenia gravis.
    Zouvelou V; Rentzos M; Toulas P; Evdokimidis I
    J Neuroimaging; 2011 Jul; 21(3):303-5. PubMed ID: 20002967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effect of intravenous immunoglobulin on anti-MuSK antibody-positive myasthenia gravis.
    Shibata-Hamaguchi A; Samuraki M; Furui E; Iwasa K; Yoshikawa H; Hayashi S; Yamada M
    Acta Neurol Scand; 2007 Dec; 116(6):406-8. PubMed ID: 17986100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab in the treatment of MuSK antibody-positive myasthenia gravis.
    Stein B; Bird SJ
    J Clin Neuromuscul Dis; 2011 Mar; 12(3):163-4. PubMed ID: 21321497
    [No Abstract]   [Full Text] [Related]  

  • 8. Anti-MuSK antibodies in a case of ocular myasthenia gravis.
    Bennett DL; Mills KR; Riordan-Eva P; Barnes PR; Rose MR
    J Neurol Neurosurg Psychiatry; 2006 Apr; 77(4):564-5. PubMed ID: 16543546
    [No Abstract]   [Full Text] [Related]  

  • 9. Selective response to rituximab in a young child with MuSK-associated myasthenia gravis.
    Govindarajan R; Iyadurai SJ; Connolly A; Zaidman C
    Neuromuscul Disord; 2015 Aug; 25(8):651-2. PubMed ID: 25998611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longstanding and Refractory Anti-Muscle Specific Tyrosine Kinase Antibody-Associated Myasthenia Gravis (Anti-MuSK-MG) in a Child Successfully Treated with Rituximab.
    Weger S; Appendino JP; Clark IH
    J Binocul Vis Ocul Motil; 2019; 69(1):26-29. PubMed ID: 30811277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transient neonatal myasthenia gravis in a baby born to a mother with new-onset anti-MuSK-mediated myasthenia gravis.
    O'carroll P; Bertorini TE; Jacob G; Mitchell CW; Graff J
    J Clin Neuromuscul Dis; 2009 Dec; 11(2):69-71. PubMed ID: 19955986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab in the management of refractory myasthenia gravis.
    Zebardast N; Patwa HS; Novella SP; Goldstein JM
    Muscle Nerve; 2010 Mar; 41(3):375-8. PubMed ID: 19852027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab.
    Hain B; Jordan K; Deschauer M; Zierz S
    Muscle Nerve; 2006 Apr; 33(4):575-80. PubMed ID: 16323216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Muscle atrophy in muscle-specific tyrosine kinase (MuSK)-related myasthenia gravis.
    Moon SY; Lee SS; Hong YH
    J Clin Neurosci; 2011 Sep; 18(9):1274-5. PubMed ID: 21741841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab is successful in an HIV-positive patient with MuSK myasthenia gravis.
    Kuntzer T; Carota A; Novy J; Cavassini M; Du Pasquier RA
    Neurology; 2011 Feb; 76(8):757-8. PubMed ID: 21339503
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience.
    Pasnoor M; Wolfe GI; Nations S; Trivedi J; Barohn RJ; Herbelin L; McVey A; Dimachkie M; Kissel J; Walsh R; Amato A; Mozaffar T; Hungs M; Chui L; Goldstein J; Novella S; Burns T; Phillips L; Claussen G; Young A; Bertorini T; Oh S
    Muscle Nerve; 2010 Mar; 41(3):370-4. PubMed ID: 19882635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MuSK antibody positive myasthenia gravis plasma modifies MURF-1 expression in C2C12 cultures and mouse muscle in vivo.
    Benveniste O; Jacobson L; Farrugia ME; Clover L; Vincent A
    J Neuroimmunol; 2005 Dec; 170(1-2):41-8. PubMed ID: 16213598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experience with patients with anti-MUSK antibody positive myasthenia gravis.
    Sundar U; Shaunbhag P; Lakkas Y; Shrivastava M; Shah A; Vaidya M; Asole D
    J Assoc Physicians India; 2010 Oct; 58():640-2. PubMed ID: 21510119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose intravenous immunoglobulin for the treatment of MuSK antibody-positive seronegative myasthenia gravis.
    Takahashi H; Kawaguchi N; Nemoto Y; Hattori T
    J Neurol Sci; 2006 Sep; 247(2):239-41. PubMed ID: 16876198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-MuSK positivity on plasmapheresis liquid in a double seronegative myasthenia gravis patient.
    Renard D; Candon S; Jacob M; Trusson R; Reboul P
    Acta Neurol Belg; 2018 Mar; 118(1):119-120. PubMed ID: 28608313
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.